Adjuvant chemotherapy for patients with soft tissue sarcoma.
Forty patients with soft tissue sarcoma (Enneking's stage I and II) were treated in our department between 1965 and 1992. We administered VACA regimen (composed of vincristine, actinomycin-D, cyclophosphamide, and doxorubicin) to 14 of 40 patients. Among 40 patients, the 5-year survival rate was 56% in 14 patients with chemotherapy and 39% in 26 without chemotherapy (p < 0.02). In 32 patients of Stage II, the 5-year survival rate was 40% in 11 patients with chemotherapy and 31% without chemotherapy (p < 0.05). The improvement of the survival rate was due to delay in the development of lung metastases (chemotherapy group: 21.2 months after first visit, non-chemotherapy group: 9.4 months) and prolongation of the survival period after metastases (chemotherapy group: 26 months, non-chemotherapy group: 7.4 months).
Ozaki
T
T
Department of Orthopaedic Surgery, Okayama University Medical School, Japan.
Sugihara
S
S
Hamada
M
M
Nakagawa
Y
Y
Inoue
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide